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Abstract
The process of epithelial-to-mesenchymal transition (EMT) in cancer is a well-described process whereby epithelial
tumour cells undergo molecular/phenotypic changes and transition to a mesenchymal biology. To aid in the
transcriptional characterisation of this process, gene expression signatures have been developed that attribute
a relative EMT score to samples in a given cohort. We demonstrate how such EMT signatures can identify
epithelial cell line models with high levels of transition but also highlight that, unsurprisingly, fibroblast cell
lines, which are inherently mesenchymal, have a higher EMT score relative to any epithelial cell line studied. In line
with these data, we demonstrate how increased tumour stromal composition, and reduced epithelial cellularity,
significantly correlates with increasing EMT signature score, which is evident using either in silico subtyping
analysis (p< 0.00001) or in situ histopathological characterisation (p< 0.001). Considered together, these results
reinforce the importance not only of interdisciplinary research to correctly define the nature of EMT biology
but also the requirement for a cadre of multidisciplinary researchers who can analyse and interpret the underlying
pathological, bioinformatic and molecular data that are essential for advancing our understanding of the malignant
process.
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of Pathological Society of Great Britain
and Ireland.
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Introduction
Due to the decreasing cost of generating molecular
information, large repositories [such as The Cancer
Genome Atlas (TCGA) and Gene Expression Omnibus
(GEO)] now provide access to semi-resolved molecular
data. This explosion in data availability has created a
bottleneck in the cancer research pipeline as a large
proportion of traditional ‘wet-lab’ molecular biologists
are unable to independently perform the complex bioin-
formatic interrogation required to maximise the value
of this freely available data. Although pathologists
perform diagnostic assessments of tissue following
initial processing, the biological interrogation of these
samples is frequently undertaken in a manner that
fails to account for the fundamental tumour pathology
by researchers with a predominantly computational
biology or bioinformatics background, with input from
molecular biologists. The multidimensional nature
of the sample-processing pipeline, involving input
from pathologists, geneticists and bioinformaticians,
coupled with the data capture, analysis and elucidation
can result in different biological interpretations that
may be irrelevant to the disease setting because they
are focussed on the incorrect cell-of-origin. To over-
come this, collaboration and communication between
all the sub-disciplines involved in data generation
and analysis is required.
Through examples, this study examines the use
of transcriptional classification, with a focus on
epithelial-to-mesenchymal transition (EMT) gene
expression signatures in colorectal cancer (CRC) as
Morris and Kopetz recently commented on how the ‘dis-
tinctions between mesenchymal and EMT signatures
are commonly blurred in the gene expression literature’
[1]. In this study, we demonstrate how a disconnect
between pathological/experimental ‘wet-lab’ research
and data processing/bioinformatics ‘dry-lab’ analy-
sis can introduce potential confounding errors in the
interpretation of gene expression signatures in tumour
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cohorts and the understanding of molecular subtypes
in cancer.
Materials and methods
CRC transcriptional profiles
All public datasets were downloaded from GEO (www
.ncbi.nlm.nih.gov/geo/) or ArrayExpress (www.ebi
.ac.uk/arrayexpress/) using the indicated accession
numbers:
E-MTAB-863: 215 stage II colon tumours tran-
scriptionally profiled using the Almac CRC Disease
Specific Array (DSA; Almac, Craigavon, Northern
Ireland, UK); GSE103479: 156 stage II/III colorectal
tumours transcriptionally profiled using the Almac
Xcel array (Almac, Craigavon, Northern Ireland, UK);
and GSE39396: Fluorescence-Activated Cell Sorting
(FACS) separated six fresh colorectal tumours into
endothelial (CD31+), epithelial (EPCAM+), leukocyte
(CD45+) and fibroblast (FAP+) populations, followed
by transcriptional profiling using the Affymetrix HT
HG-U133 Plus PM array (Santa Clara, CA, USA).
Cancer Cell Line Encyclopedia
RMA-normalised mRNA expression microarray data
were obtained from the Cancer Cell Line Encyclopedia
(CCLE) via https://data.broadinstitute.org/ccle_legacy_
data/mRNA_expression/CCLE_Expression_2012-09-
29.res.
ssGSEA EMT signature score
Single-sample gene set enrichment analysis was per-
formed using the ssGSEAProjection module
on GenePattern (https://genepattern.broadinsti
tute.org/) with the EMT gene set (HALLMARK_EPITH
ELIAL_MESENCHYMAL_TRANSITION; MSigDB
v6.1).
More details of the datasets and methods for data
normalisation; clustering analysis; and calculation of
relative gene expression levels, signature scores for
cancer-associated fibroblast (CAF) and endothelial
cells, immune and stromal cell correlations, consensus
molecular subtype (CMS) and epithelial cell fraction
are provided in supplementary material, Supplementary
materials and methods.
Results
Assessment of EMT signature score in cell line
models
The CCLE provides molecular data from ∼1500 cancer
cell lines. Using this database, we selected transcrip-
tional profiles for 61 CRC cell line models for the
assessment of EMT signature scores using the ssGSEA
Table 1. Histological characteristics and lineage information for a
subset of the CCLE cell lines according to ssGSEA EMT signature
score
Cell line EMT score Description
Hs 698.T 7675.53 Colon; derived from metastatic site:
connective tissue
Hs 255.T 7527.33 Colon; morphology: fibroblast
Hs 675.T 6884.19 Colon; morphology: fibroblast
MDST8 4654.13 Colon; cell type: epithelial-like
SNU-1197 2665.23 Colon; cellular morphology: epithelial
GP2d −1452.18 Colon; cell type: epithelial
SNU-283 −1467 Colon; cellular morphology: epithelial
SW403 −1804.08 Colon; morphology: epithelial
SNU-283 −1804.47 Colon; cellular morphology:
lymphoblast-like, round
CCK-81 −2091.15 Colon; adenocarcinoma
The upper section displays EMT scores and information for the five highest
ranking cell lines, and the lower section displays EMT scores and information
for the five lowest ranking cell lines.
EMTHallmark signature [2], which was chosen because
it is derived from multiple founder datasets, followed by
testing and independent validation using experimental
data. Although there is no defined threshold for what
constitutes a ‘high’ EMT score, the majority of cell lines
had an ssGSEA EMT score below the arbitrary figure of
1000, while three cell lines demonstrated EMT scores
>6000 (Hs 698.T: 6884, Hs 255.T: 7676, Hs 675.T:
6884; Table 1 and Figure 1A). Investigation of the
origin/histology of these cell lines demonstrated that,
unlike the other epithelial cell lines investigated, these
three were described as either fibroblasts or connective
tissue from the American Tissue Culture Collection
(ATCC). These cell line findings highlight an important
issue. Although fibroblast (non-epithelial) cell popula-
tions can easily be excluded from a cell line experiment
aimed at identifying EMT signatures in epithelial cells,
this is not possible when dealing with tumour samples.
Even with the attempted enrichment for the epithelial
cell population by macrodissection, there is inevitable
and innate variation in fibroblast abundance within the
tumour microenvironment (TME). Not considering this
variation may result in an inaccurate interpretation of
EMT data derived from samples within a tumour tissue
cohort.
To validate our hypothesis, we assessed the EMT sig-
nature genes in a 24-sample discovery cohort, derived
from six CRC patients, where fibroblast, endothelial
cell, epithelial cell and leukocyte populations were iso-
lated and transcriptionally profiled. This assessment
demonstrated that >75% of the genes within the EMT
signature were associated with non-epithelial lineages
of the TME (Figure 1B), predominantly the CAF com-
ponent (Figure 1C).
EMT signature score is associated with stromal
components of the TME
Based on these preliminary data, we attempted to com-
prehensively validate our findings in two cohorts:
GSE103479 (n= 156) and E-MTAB-863 (n= 215).
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 246: 422–426
on behalf of Pathological Society of Great Britain and Ireland. www.pathsoc.org www.thejournalofpathology.com
424 AMB McCorry et al
Figure 1. (A) Microarray profiles from the 61 CRC cell line models
within the CCLE were scored using the ssGSEA EMT signature,
followed by ranking from high to low according to the resulting
EMT score. Red dots indicate cell lines with fibroblast or connective
tissue origin. (B) Semi-supervised hierarchical clustering of the
EMT signature genes in the GSE39396 cohort demonstrates the
stromal (particularly fibroblast) origin of transcription in CRC.
GSE39396 contains n= 24 transcriptional profiles from isolated
epithelial, endothelial, leukocyte and fibroblast lineages from six
freshly resected colorectal tumour tissue samples. (C) Median
relative expression of EMT signature genes in each individual
lineage as in (B).
We performed ssGSEA EMT signature assessment, fol-
lowed by correlation with fibroblast-specific scores from
the microenvironment cell populations counter (MCP)
[3] alongside the CAF and cancer-associated endothe-
lial (CAE) signatures previously generated from CRC
tissue that underwent FACS enrichment and subsequent
transcriptional profiling [4,5]. These analyses confirmed
that the EMT signature is associated with the stromal
component of a tumour, with a significant correlation
between EMT scores and MCP-fibroblast (p< 0.00001;
Figure 2A), CAF (p< 0.00001; Figure 2B) and CAE
levels (p< 0.00001; Figure 2C). Importantly, the EMT
score was negatively correlated with epithelial cell
levels (assessed by the tumour purity ESTIMATE algo-
rithm) [6] (p< 0.00001; Figure 2D, see supplementary
Figure 2. EMT signatures classification of microarray profiles from
two independent CRC cohorts (E-MTAB-863 and GSE103479) cor-
related to: (A) MCP-counter fibroblast score, (B) CAF signature
score, (C) endothelial signature score and (D) tumour purity (epithe-
lial) ESTIMATE score. E-MTAB-863 contains microarray profiles
from 215 stage II FFPE colon cancer tumours, transcriptionally pro-
filed using the Almac Colorectal Cancer DSA platform. GSE103479
contains microarray profiles from 156 stage II and III fresh frozen
colon cancer tumours, transcriptionally profiled using the Almac
Xcel array platform.
material, Figures S1 and S2), further supporting the
hypothesis that tumoural EMT assessment is a measure
of stromal abundance rather than epithelial transition.
Pathological assessment of tumour tissue according
to EMT signature score
Transcriptomic interrogation of CRCs has demon-
strated four CMSs [7]. Two of these correspond
to well-characterised histological subtypes: CMS1
(immune-rich) and CMS4 (stromal, particularly
fibroblast-rich), alongside two epithelial-rich sub-
types: CMS2 and CMS3. Using the GSE103479 cohort,
in line with findings from the CMS study, we confirmed
the significant overlap between high EMT score and the
fibroblast-rich CMS4 subtype (Figure 3A. p< 0.00001)
and low EMT scores associated with the epithelial-rich
CMS2/CMS3 tumour subtypes. Next, we performed an
assessment of the CRC intrinsic subtypes (CRIS) that
© 2018 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd J Pathol 2018; 246: 422–426
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Figure 3. (A) CMS classification of the GSE103479 cohort and
alignment with normalised ssGSEA EMT signature score (left). Box-
plot detailing ssGSEA raw scores for individual samples according
to CMS classification, indicating median, upper/lower quartile and
max/min values. *****p< 0.00001. (B) H&E images of tumour sam-
ples with the highest and lowest ssGSEA EMT signature scores.
(C) Pathologist scoring, blinded to tumour EMT classification, indi-
cates significant association between EMT signature score and
tumour/stromal content of tumour tissue. ***p< 0.001.
previously identified increased intrinsic EMT signalling
within CRIS-B tumours [8,9]. Results indicated that,
while CMS4 tumours were distributed across all CRIS
subtypes, CRIS-D contained the largest relative number
of CMS4s (44%; see supplementary material, Figure
S3A). CRIS-B tumours had a significantly higher over-
all EMT score compared to CRIS-A (p< 0.01), CRIS-C
(p< 0.05) and CRIS-E (p< 0.01) (see supplementary
material, Figure S3B), likely due to their high intrinsic
EMT signalling. The highest EMT-scoring tumours
were significantly associated with the stromal-rich
CMS4 subtype (p< 0.00001 compared to all other CMS
subtypes), with only one CMS4 tumour scoring below
the median, reinforcing the hypothesis that the stroma
makes a more significant contribution to an individual
tumour’s EMT score regardless of intrinsic subtype
(Figure 3A, see supplementary material, Figure S3B).
We then selected cases with the highest (n= 8) and
lowest (n= 8) ssGSEA EMT signature scores from this
cohort and performed a pathological assessment of the
epithelial and stromal composition of the tumour tissue
used to generate these transcriptional profiles, with
the assessing pathologist blinded to all transcriptional
data and classifications (Figure 3B). In support of our
hypothesis, tumours with the lowest EMT scores were
significantly associated with the highest epithelial
cellularity (Figure 3C. p< 0.001; tumour epithelial
cellularity 60–90%), even when samples containing
high immune infiltrate (making cellularity estimation
difficult) are considered (see supplementary material,
Figure S5. p< 0.01).
Discussion
The EMT-like molecular subgroup has been identi-
fied in a number of cancers, including those arising
in the colorectum, breast, ovary, prostate and lung. [10]
This subgroup is associated with poor prognosis and
has been widely misinterpreted to represent a class
of tumours where epithelial cells have undergone a
widespread transition to a mesenchymal phenotype,
resulting in more invasive and aggressive tumour
behaviour. The use of inaccurate nomenclature to
describe these signatures has been further confounded
by the increasing distance between the ‘end user’
interpreting the findings and the preceding steps of
tissue procurement and handling, molecular profil-
ing and data generation/analysis. Although all these
steps may still be performed by the wet-lab biologist
when low-throughput single-biomarker studies are
required, given the multidisciplinary approach required
for comprehensive omics-level tumour profiling anal-
ysis, these steps are increasingly being performed
by core units, service providers or stand-alone bioin-
formatics departments/units. This potential lack of
multidisciplinary oversight, from tissue collection to
bioinformatics reporting, can result in the misinterpreta-
tion of the underlying pathology/biology ensuing from
the molecular data.
The data presented here do not challenge the clin-
ical importance of the EMT subtype [10,11]; rather,
they highlight how the alignment of predefined sig-
natures, such as EMT, in either cancer cell lines or
cancer tissue samples can result in the identifica-
tion of similar subgroups (EMT-high) based on two
inherently different underlying biologies, namely, true
EMT or innate high cancer fibroblast composition.
Our data are in line with previous findings from the
CMS consortium, which demonstrated an enrich-
ment of CAF/CAE in the stromal-rich CMS4 subtype
(or equivocal Stem/Serrated/Mesenchymal subtypes)
using either in silico or histological assessment [4,7].
Importantly, however, we now demonstrate that the
correlation between stromal infiltration and EMT sig-
nature is predominantly due to the fibroblast content
per se and not a transition of epithelial cells within
the tumour. We do not definitively rule out that there
could be some contribution to the EMT score from
epithelial cells undergoing true EMT within a tumour
mass, but we consider this a relatively rare event. We
observed that even the highest EMT scores achieved
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by epithelial cells were low compared to those seen in
fibroblasts, suggesting that, in line with our previous
work on the stability of subtypes at multiple regions of
tumour tissue, [12] subtle changes in tumour–stroma
ratio can contribute more significantly to the EMT
signature than epithelial cells undergoing transition.
Thus, macrodissection of tumour samples to enrich
for the epithelial tumour cell population is likely to
negatively influence the EMT score. Further detailed
investigation of the stromal-rich CMS4 subtype in CRC
has demonstrated the clinical importance of not only
the CAF component but also the interplay between the
milieu of inflammatory and endothelial lineages and
the associated cytokine production [13]. Our study,
and that of Becht and colleagues [13], emphasises the
importance of integrating comprehensive pathological
assessment with molecular subtyping in order to fully
exploit and most accurately interpret such data and their
clinical implications.
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